We came across a bullish thesis on Protagonist Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics, Inc.'s share was trading at $85.64 as of December 1st. PTGX’s trailing and forward P/E were 128.19 and 26.39, respectively according to Yahoo Finance.
[caption id="attachment_913574" align="aligncenter" width="750"]Protagonist Therapeutics (PTGX) represents a rare convergence of biotech innovation and pharmaceutical execution, built around a proprietary...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.